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The exon 14 JAK2 V617F mutation has been well established as a driver mutation in polycythemia vera
(PV) and other myeloproliferative neoplasms. JAK2 exon 12 mutations have also been implicated in PV,
although patients with these mutations may show isolated erythrocytosis. Recently additional JAK2point
mutations have been described―all in regions encoding the pseudokinase domain that regulates the
tyrosine kinase activity of JAK2. We present a case of a patient with erythrocytosis and an exon 13 G571S
mutation, and discuss the putative role of this mutation in myeloproliferative neoplasms.
& 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Report
A 49-year-old woman with past medical history of total thyr-
oidectomy due to papillary thyroid carcinoma was found to have
an elevated hemoglobin level. The patient reported to being in her
usual health and denied any erythema, ﬂushing, intolerance or
irritation with hot showers, any shortness of breath or limitations
in her daily activity. In addition, the patient denied any changes in
her appetite, and reported no bowel or bladder dysfunction, and
no change in weight. Patient noted isolated dyspnea 4–6 weeks
ago during unusually strong exertion at work that ultimately re-
solved with rest. Physical examination of the patient was within
normal limits. An abdominal ultrasound examination showed a
spleen within normal limits in size.
At presentation, her complete blood count was as follows:
hemoglobin 16.8 g/dL, hematocrit 49.8%, MCV 107.9 fL, MCH
36.4 pg, RDW 13%, leukocytes 7.6109/L, platelets 171109/L;
with a differential showing granulocytes 72%, lymphocytes 17%,
monocytes 9%, eosinophils 1%, basophils 1%. Other laboratory va-
lues were as follows: TSH 0.34 μIU/mL, fT4 1.9 ng/dL, vitamin B12
294 pg/mL, folate 7.8 ng/mL, and erythropoietin 15.6 mIU/mL.
The bone marrow core biopsy was normocellular for age (50%).
The aspirate smear showed trilineage hematopoiesis with pro-
gressive maturation of the myeloid and erythroid precursors. The
myeloid to erythroid ratio was 3.2 to 1. Blasts were not increased
(o1%). There was no signiﬁcant dyserythropoiesis. Occasional
hypolobated megakaryocytes were present but mostLtd. This is an open access article umegakaryocytes displayed normal morphology. Iron stain showed
increased storage iron and decreased sideroblastic iron. Reticulin
stain showed a very mild focal increase in reticulin ﬁbers. Flow
cytometric analysis performed on the bone marrow aspirate did
not show a signiﬁcant increase in the blast population. There was
no evidence of a B-cell monoclonal population or a T-cell ab-
normality. Cytogenetic analysis showed a normal female kar-
yotype. Molecular testing on the patient’s plasma (RT-PCR ampli-
ﬁcation followed by sequencing, Quest Diagnostics) showed pre-
sence of at least one mutated JAK2 G571S allele in exon 13. The
V617F mutation and exon 12 mutations were not detected. We
were unable to perform a comprehensive genomic analysis on our
patient to identify any additional mutations.
The patient’s erythrocytosis has persisted for three years since
the initial encounter, and has been treated with phlebotomy alone.
Initially the patient received weekly phlebotomies. Currently, the
patient receives phlebotomies as needed, with a target hematocrit
of less than 45% [1].2. Discussion
The exon 14 JAK2 V617F mutation is seen in 95% of all PV pa-
tients, and approximately 50% of patients with essential throm-
bocythemia (ET) and primary myeloﬁbrosis (PMF) [2]. About 3% of
the patients have JAK2 exon 12 mutations. Patients with exon 12
mutations often present with isolated erythrocytosis and may not
meet the diagnostic criteria for polycythemia vera [3–5]. In addi-
tion to these mutations, Ma et al. discovered several mutations in
the pseudokinase domain coding region of JAK2 including thender the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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The JAK2 G571S mutation is next to a tyrosine residue at po-
sition 570 (Y570). Y570 lies within the JH2 inhibitory domain and
is thought to be the most important phosphorylation site for
downregulation of JAK2 activity [7,8]. Biochemical studies show
that autophosphorylation of Y570 rapidly downregulates kinase
activity. The adjacent G571S mutation may cause a conﬁrmation
change preventing Y570 phosphorylation, leading to constitutive
JAK2 signaling. However, classical in vitro studies do not show
activation of STAT5 [9] suggesting that the activating effect of the
G571S mutation would be weak.
The G571S mutation is extremely rare. In the study by Ma et al.
[6] approximately 20,000 blood samples from patients with sus-
pected myeloproliferative neoplasms were analyzed for JAK2
mutations. The G571S mutation was found in only 3 samples,
compared to the V617F mutation which was positive in 4280
samples. A recent report describes a family with germline G571S
mutations [10], none of whom showed erythrocytosis. The G571S
mutation was also found in two patients with “triple-negative” ET
and PMF [9].
To our knowledge this is the ﬁrst case description of a patient
with erythrocytosis and a G571S JAK2 mutation. Based on the
limited penetrance [10] and in vitro studies [9], it is unlikely that
the G571S mutation is the sole driver of erythropoiesis. We hope
that this report will facilitate additional studies of patients with
the G571S and related exon 13 JAK2 mutations, so as to ascertain
their role in the pathogenesis of myeloproliferative disorders.References
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